Extended Data Fig. 1: Distribution of CH by germline carrier status in the UK Biobank.

a. Prevalence by age for CH in gene with known relevance to both myeloid and lymphoid malignancies, only myeloid malignancies, only lymphoid malignancies or solid tumors (left), and mCA in autosomal chromosomes, loss of X chromosome, or loss of Y chromosome (right). Data are presented as the CH prevalence fitted using polynomial regression of degree 2 (center line) ± 95% confidence interval (CI) for the fitted line (error bands). b. Shown in red and blue are the odds ratios (center dot) and 95% CI (error bars) for CH categories were calculated using multivariable Firth’s bias-reduced logistic regression among people with dominant (n = 33,106) or recessive (n = 43,981) germline variant compared to those without germline variant (n = 354,774) after adjustment for age at blood draw, the first three genetic principal components, and exome sequencing batch. *Q value (FDR-corrected P value) < 0.05, **Q < 0.01, ***Q < 0.001. See Supplementary Table 9 for exact Q values. c. Comparison of the proportion of people with 1, 2 or 3 + CH and the distribution of maximum variant allele frequency between people with dominant germline variant (n = 33,106) and people with no germline variant (n = 354,774). P values for the associations between the number of CH and having dominant germline variant were derived from logistic regression and P values for the association between the maximum VAF of CH and having dominant germline variant were derived from linear regression, with adjustment for the above covariates. Center line represents median. Box limits represent upper and lower quartiles. Whiskers represent 1.5x interquartile range. Cell fractions of mCA-auto were not included due to inaccuracy. *P < 0.05, **P < 0.01, ***P < 0.001. Two-sided P values not corrected for multiple hypothesis testing.